跳到正文
原文
Nature 健康护理主题·· 2026-10-07AI 评分34

Nature:TRI-611 分子胶降解剂靶向 ALK 耐药,临床前针对 TKI 耐药变异

Molecular glue targets ALK resistance

AI 导读

Conery 等在 Nature 报告 TRI-611 的发现与临床前表征:这是一种选择性、脑渗透性分子胶降解剂,靶向包括 TKI 耐药变异在内的 ALK 融合蛋白。ALK 融合蛋白是非小细胞肺癌(NSCLC)的致癌驱动因素,ALK TKI 已改善患者结局,但 ALK 激酶域突变等获得性耐药、毒性及部分 TKI 中枢神经系统穿透有限仍是挑战。

正文
  • RESEARCH HIGHLIGHT
  • 07 October 2026

By

  1. M. Teresa Villanueva

Anaplastic lymphoma kinase (ALK) fusion proteins are key oncogenic drivers in a subset of non-small-cell lung cancers (NSCLCs), and tyrosine kinase inhibitors (TKIs) targeting ALK have significantly improved patient outcomes. However, acquired resistance — often owing to mutations in the ALK kinase domain — toxicity and limited central nervous system (CNS) penetration of some TKIs, which can hinder the treatment of brain metastases, remain challenges. Now, writing in Nature, Conery et al. report the discovery and preclinical characterization of TRI-611, a selective, brain-penetrant molecular glue degrader (MGD) that targets ALK fusion proteins, including TKI-resistant variants.

doi: https://doi.org/10.1038/d41573-026-00163-w

Related Articles

Subjects

Latest on:

来源:Nature 健康护理主题 · nature.com